Clinical Trials Browser

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT03693612 2024-08-28

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

Phase 1/2 Completed

26 enrolled 47 charts

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms

NCT00543387 2024-06-05

MK-5108-001

Phase 1 Completed

35 enrolled 15 charts

Tumor-Agnostic

Neoplasms

NCT05094804 2023-11-02

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

Phase 1/2 Unknown

172 enrolled

DermatologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Leiomyosarcoma, Liposarcoma, Melanoma, Neoplasm Metastasis, Neoplasms

NCT05553808 2023-01-19

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1

Phase 2 Completed

105 enrolled 31 charts

Tumor-Agnostic

Neoplasms

NCT01920061 2022-09-13

A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

Phase 1 Completed

110 enrolled 80 charts

Breast

Neoplasm Metastasis, Neoplasms, Triple Negative Breast Neoplasms

NCT01362374 2022-01-12

Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors

Phase 1 Completed

122 enrolled

Tumor-Agnostic

Neoplasms

NCT02117024 2020-02-05

A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

Phase 2 Terminated

66 enrolled 17 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03057366 2019-11-18

A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors

Phase 1 Completed

8 enrolled 26 charts

Tumor-Agnostic

Neoplasms

NCT00848718 2019-11-12

MK-2206-003

Phase 1 Completed

77 enrolled 24 charts

Tumor-Agnostic

Neoplasms

NCT01868022 2019-08-19

Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling

Phase 1 Completed

65 enrolled 32 charts

Tumor-Agnostic

Neoplasms

NCT02322281 2019-08-14

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Phase 3 Terminated

149 enrolled 17 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Recurrence

NCT00704821 2019-05-10

PTC299 for Treatment of Advanced Cancer

Phase 1 Terminated

76 enrolled

Tumor-Agnostic

Neoplasms

NCT01376310 2019-02-19

GSK1120212 Rollover Study

Phase 2 Terminated

159 enrolled 9 charts

Tumor-Agnostic

Neoplasms

NCT00148902 2017-12-06

Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)

Phase 1 Completed

52 enrolled

Breast

Breast Neoplasms, Neoplasms

NCT01472016 2017-11-21

Study of ABT-700 in Subjects With Advanced Solid Tumors

Phase 1 Completed

74 enrolled

Tumor-Agnostic

Neoplasms

NCT01192165 2017-11-13

Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

Phase 1 Completed

169 enrolled

Tumor-Agnostic

Neoplasms

NCT01837667 2017-01-24

Phase I Study of LB-100 With Docetaxel in Solid Tumors

Phase 1 Completed

29 enrolled

Tumor-Agnostic

Neoplasms

NCT00811993 2016-11-02

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors

Phase 1 Terminated

104 enrolled

Tumor-Agnostic

Neoplasms

NCT00519285 2016-07-22

VENICE

Phase 3 Completed

1,224 enrolled 21 charts

Genitourinary

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT00705874 2016-07-21

Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma

Phase 1 Completed

172 enrolled 13 charts

Lymphoid

Lymphoma, Neoplasms

NCT01251653 2016-05-30

A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel

Completed

94 enrolled 33 charts

Tumor-Agnostic

Neoplasms

NCT00487786 2016-01-18

Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer

Phase 1 Completed

64 enrolled

Tumor-Agnostic

Neoplasms

NCT00514267 2015-08-13

An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors

Phase 1/2 Completed

32 enrolled

Genitourinary

Neoplasms, Prostatic Neoplasms

NCT02171676 2014-06-24

BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors

Phase 1 Completed

40 enrolled

Tumor-Agnostic

Neoplasms

NCT02171741 2014-06-24

Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors

Phase 1 Completed

31 enrolled

Tumor-Agnostic

Neoplasms

NCT00399087 2014-02-13

Phase I Trial of Docetaxel With Perifosine

Phase 1 Completed

39 enrolled

Tumor-Agnostic

Neoplasms

NCT00808418 2014-02-03

A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer

Phase 1 Completed

34 enrolled

Genitourinary

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT00545246 2013-10-16

A Phase I Study of Intravenous Aflibercept in Combination With Docetaxel in Japanese Cancer Patients

Phase 1 Completed

12 enrolled

Tumor-Agnostic

Neoplasms

NCT01095302 2013-10-16

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors

Phase 1 Completed

11 enrolled

Tumor-Agnostic

Neoplasms

NCT00322400 2013-07-31

Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer

Phase 1 Completed

46 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT01604863 2012-11-01

A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies

Phase 1 Suspended

54 enrolled

GenitourinaryOther solid neoplasmThoracic

Lung Neoplasms, Mesothelioma, Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT01204996 2012-05-30

A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors

Phase 1 Completed

53 enrolled

Tumor-Agnostic

Neoplasms

Clinical Trials

VIRO-25

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

A Study of ASP3082 in Adults With Advanced Solid Tumors

ILUSTRO

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

CAMPFIRE

A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

KYANITE-1

LIVIGNO-3

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

IVY

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

MK-5108-001

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1

A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors

A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors

MK-2206-003

Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

PTC299 for Treatment of Advanced Cancer

GSK1120212 Rollover Study

Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)

Study of ABT-700 in Subjects With Advanced Solid Tumors

Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

Phase I Study of LB-100 With Docetaxel in Solid Tumors

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors

VENICE

Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma

A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel

Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer

An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors

BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors

Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors

Phase I Trial of Docetaxel With Perifosine

A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer

A Phase I Study of Intravenous Aflibercept in Combination With Docetaxel in Japanese Cancer Patients

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors

Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer

A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies

A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors